The FDA has removed the partial hold imposed on three clinical trials of OncoMed Pharmaceuticals' investigational cancer treatment vantictumab. The agency placed the hold after reports of bone-related side effects tied to vantictumab and another one of the company's drugs. OncoMed said patient enrollment is expected to reopen in the next several weeks after approval of the revised trial protocol.

Full Story:

Related Summaries